Imidazo[1,2-a]pyridine-3-acetic acid methyl ester

We are Imidazo[1,2-a]pyridine-3-acetic acid methyl ester CAS:1244029-51-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Imidazo[1,2-a]pyridine-3-acetic acid methyl ester
CAS.NO:1244029-51-3
Synonyms:Imidazo[1,2-a]pyridine-3-acetic acid methyl ester
Methyl imidazo[1,2-a]pyridin-3-ylacetate
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Molecular Formula C10H10N2O2
Molecular Weight 190.199
 
Specification:
Appearance:White crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Minodronic Acid(CAS:180064-38-4).

Imidazo[1,2-a]pyridine-3-acetic acid methyl ester


Related News: We manufacture APIs and drug manufacturers make medicines from APIs.2-Chloro-5-hydroxypyridine The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.3-tri(propan-2-yloxy)silylpropyl 2-methylprop-2-enoate CAS:80750-05-6 DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.5-Formyl-2,3-dihydro-1-[3-(phenylmethoxy)propyl]-1H-indole-7-carbonitrile CAS:1375180-30-5 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
DL-Norvaline View Details
Ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate View Details
H-ARG-ALA-OH ACOH View Details
B-(10-[1,1′-Biphenyl]-3-yl-9-anthracenyl)boronic acid manufacturer 4-methylbenzyl alcohol manufacturer 5,6,7,8-tetrahydro-2-naphthol manufacturer Calcium 3-hydroxybutyrate manufacturer 2-(tert-butylamino)acetyl chloride,hydrochloride manufacturer